Just in the past couple of weeks, two new treatments pertaining to diabetes have been approved by the FDA. Their names: ILUVIEN and Trulicity. What they do: you’ll have to read on!
Diabetic macular edema (DME) is quite common among people with diabetes (type 1 and type 2), affecting the eyesight of an estimated 600,000 Americans. With DME, one may find it increasingly difficult to read, drive, or even to recognize familiar faces. This is due to the blood vessel leakage of diabetic retinopathy and the swelling it causes in the macula (responsible for central vision). Oftentimes DME is a gradual but painless process, only detected when blurriness gets worse and worse.
ILUVIEN, a tiny implant placed in the back of your eye by a retinal specialist, intends to combat DME. How? With ILUVIEN, a low dosage of a particular corticosteroid (anti-inflammatory) will be delivered, cutting down on the swelling.
Watch the video for a personal account from a sufferer of DME.
Made by Eli Lilly and Company, Trulicity is a glucagon-like peptide-1 (GLP-1). GLP-1 is a hormone naturally released in the intestine. When carbohydrates are absorbed in the intestine, GLP-1 is responsible for fueling the release of insulin from pancreatic beta cells.
Trulicity is an injectable treatment specifically for adults with type 2 diabetes and will be available later in 2014. It will not require mixing, or a needle attachment. Instead, it’ll be a single-use pen administered once a week, at any time of the day.